26 results
8-K
BTAX
Biostax Corp.
19 Feb 20
Immune Therapeutics, Inc. Appoints New Independent Director
4:31pm
expertise in a complex capital markets environment with added exposure on both the national & international stage, coverage experience across primary
8-K
EX-10.1
BTAX
Biostax Corp.
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
damage caused by alcohol abuse, hepatitis, cirrhosis, bacterial infection or environment toxins
India
3435/DELP/2004
IN240229
(License out)
官網沒有從 … or environment toxins
Japan
JP5438250
(License out)
官網資訊權利者為タイワンジェ
ファーマシュティカルズ
カンパニー リミテッド
(2022/4/20瀏覽)
Liver and kidney damages associated
10-K
2013 FY
BTAX
Biostax Corp.
31 Mar 14
Annual report
12:00am
and dendritic cells which are present in tissues in contact with the external environment and have garnered the most research interest as antigen … operating results or cause us to fail to meet our reporting obligations.
Failure to achieve and maintain an effective internal control environment could
10-12G
65pmmyg4ka6di3rhvnhc
22 Apr 13
Registration of securities
12:00am
10-12G/A
vbezr ed5zr1g
7 Jun 13
Registration of securities (amended)
12:00am
10-12G/A
tl1jej
18 Jul 13
Registration of securities (amended)
12:00am
10-12G/A
7zi13aoocsnrc7 96
23 Aug 13
Registration of securities (amended)
12:00am
10-12G/A
2evovz5dt15how u08u
23 Jan 14
Registration of securities (amended)
12:00am
10-12G/A
9kq6j
7 Feb 14
Registration of securities (amended)
12:00am
10-12G/A
xyu jh237j7us
21 Nov 13
Registration of securities (amended)
12:00am
10-12G/A
aauxspvys28
25 Sep 13
Registration of securities (amended)
12:00am
10-12G/A
98yf65y
11 Oct 13
Registration of securities (amended)
12:00am